Kizefma Trademark Published for Opposition

The United States Patent and Trademark Office (USPTO) has published the trademark application for 'Kizefma' (TM79437264) for opposition. This publication signifies that the application has passed initial examination and is now open to challenges from third parties. The trademark is intended for use in connection with a range of pharmaceutical and medical products, specifically monoclonal antibodies for medical purposes and pharmaceutical preparations for treating arthritis, spondylitis, psoriasis, and autoimmune diseases.

This is a routine trademark publication process. While it does not impose new regulatory obligations on entities, it is a critical step for companies operating in the pharmaceutical sector to monitor for potential conflicts with their own branding or intellectual property. The opposition period, which begins upon publication, allows interested parties to file an opposition if they believe the trademark would cause confusion or infringe on existing rights. The filing date for this application was October 16, 2025, and it was published for opposition on March 26, 2026.